BioNTech Heads Into Shareholder Vote With $1 Billion Buyback and an Oncology Pipeline Under Scrutiny

BioNTech's virtual annual meeting tests management's pivot from Covid-19 to cancer therapies; Q1 sales slump to €118M, $1B buyback announced, and board expansion proposed.

BioNTech’s transformation from pandemic poster child to oncology contender reaches a critical inflection point this week. Shareholders gather virtually on Friday for an annual meeting that will test management’s ability to steer the company through a painful revenue collapse while holding a $20 billion cash pile. The agenda includes a proposed expansion of the supervisory board and a vote to carry forward €6.9 billion in retained earnings — moves designed to lock in the strategic pivot toward cancer therapies.

The financial picture is stark. BioNTech reported first-quarter sales of just €118 million, well short of analyst expectations, as demand for its Covid-19 vaccine continues to wither. Net losses ballooned to over €530 million, underscoring the speed of the revenue cliff. Still, management reaffirmed its 2026 revenue forecast of up to $2.6 billion, betting that the pipeline will eventually fill the gap.

To back that bet with tangible capital discipline, the board has authorized a $1 billion share buyback program running through May 2027. The repurchases will target American depositary shares, each equivalent to one ordinary share, and are primarily intended to fund equity-based compensation. The timing and scale will depend on market conditions — but the authorization sends a clear signal of confidence while the stock languishes near €78.70, well below its 200-day moving average and down nearly 5% year-to-date.

Analysts remain cautious but constructive. Berenberg recently trimmed its price target to $140 yet maintains a buy rating, arguing the current valuation ignores the potential in BioNTech’s oncology pipeline. Canaccord holds a more bullish $158 target. The overriding sentiment: Covid headwinds are obscuring what could be a multi-billion-dollar cancer franchise in the making.

The supervisory board itself is reshaping to reflect that ambition. A vote on Friday will decide whether to expand the board from six to eight members, adding two specialists in clinical development. The move comes as founders Ugur Sahin and Özlem Türeci have signaled their intention to step back, a departure that rattled the stock in March and drove it to a 52-week low. Institutional investors will be watching closely to see whether the new board composition can maintain strategic continuity.

On the pipeline front, the pace is accelerating. BioNTech has launched five new pivotal trials for its bispecific antibody Pumitamig, targeting multiple tumor types. Another candidate, Gotistobart, showed a significant reduction in mortality risk for certain lung cancer patients in a late-stage study. Roughly 90% of R&D spending now flows into non-Covid programs, and the company expects to expand its late-stage clinical portfolio to 15 studies this year. Several key data readouts remain pending — results that will ultimately determine whether the $1 billion buyback and the board’s overhaul are sufficient to restore investor faith.

For now, BioNTech is buying time and talent retention with its own stock while pouring cash into the lab. The shareholder meeting on Friday is less a vote on the past year than a bet on the next decade. The oncology pivot will only succeed if the clinical data delivers.